Compare MLM & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLM | KVUE |
|---|---|---|
| Founded | 1993 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Specialty Chemicals |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.0B | 34.9B |
| IPO Year | 1996 | 2023 |
| Metric | MLM | KVUE |
|---|---|---|
| Price | $560.26 | $17.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | ★ $694.86 | $19.73 |
| AVG Volume (30 Days) | 539.6K | ★ 25.1M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | 0.59% | ★ 4.76% |
| EPS Growth | N/A | ★ 40.74 |
| EPS | ★ 18.77 | 0.76 |
| Revenue | $6,150,000,000.00 | ★ $15,124,000,000.00 |
| Revenue This Year | $11.15 | $4.80 |
| Revenue Next Year | $8.41 | $2.52 |
| P/E Ratio | $30.21 | ★ $22.96 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $441.95 | $14.02 |
| 52 Week High | $710.97 | $25.17 |
| Indicator | MLM | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 23.78 | 39.50 |
| Support Level | $560.89 | $17.14 |
| Resistance Level | $625.54 | $17.89 |
| Average True Range (ATR) | 16.75 | 0.30 |
| MACD | -6.82 | -0.11 |
| Stochastic Oscillator | 7.11 | 10.00 |
Martin Marietta Materials is one of the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). In 2024, Martin Marietta sold 191 million tons of aggregates. Martin Marietta's most important markets include Texas, North Carolina, Colorado, California, and Georgia, accounting for most of its sales. The company also uses its aggregates in its asphalt and ready-mixed concrete businesses. Martin's magnesia specialties business produces magnesia-based chemical products and dolomitic lime.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.